Cookie - 14 Days After Stem Cell Therapy
We have a 96% success rate with stem cell therapy. Every case is different, this is one of the more dramatic improvements we #39;ve seen, but it #39;s not uncommon for pets to completely regain the...

By: Newman Veterinary Centers

See the rest here:
Cookie - 14 Days After Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

06.10.14 11:38 Dow Jones Newswires

DJ Therapy decision in breast cancer: EndoPredict(R) predicts benefit from chemotherapy - Independent research group confirms chemo benefit for high-risk patients

(DGAP-Media / 06.10.2014 / 11:37)

Patients for whom EndoPredict(R) predicts a high risk of relapse have much greater benefit from chemotherapy than low-risk patients. This is the result published by an independent research group after investigating gene expression profiles and histological data of 553 patients. All patients were suffering from hormone receptor-positive and HER2/neu-negative breast cancer.

The authors conclude that a low risk EndoPredict result is a convincing reason not to give chemotherapy to a breast cancer patient. On the other hand, a high risk result is an indicator that the patient will benefit from chemotherapy.

"EndoPredict is the first test of its kind for which exclusively hormone receptor-positive and HER2/neu-negative tumours were already used during its development", says Dr. Christoph Petry, CEO of the developer company Sividon Diagnostics. "It is therefore the first gene expression test really tailor-made for those breast cancer patients who need it. We are pleased that independent scientists have now confirmed that patients for whom EndoPredict has predicted a high metastatic risk are in fact helped more by chemotherapy."

Low-risk patients according to EndoPredict have a very good prognosis, and hardly benefit from chemotherapy. "The treatment would be an unnecessary burden for the patients", explains Petry. "High-risk patients frequently have a genuine benefit from chemotherapy, as has been shown again in the recent study."

The study results are published in the Cancer Letters and can be downloadad at http://www.cancerletters.info/article/S0304-3835(14)00513-8/abstract. Franois Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum, EndoPredict Predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer, Cancer Letters (2014), http://dx.doi.org/doi: 10.1016/j.canlet.2014.09.014

Sividon Diagnostics GmbH was founded in July 2010 as a management buyout from Siemens Healthcare Diagnostics Products in Cologne, Germany. The company aims to sustainably increase the quality of therapy-accompanying diagnostics in oncology. EndoPredict(R), the first diagnostic test from Sividon, has been available since 2011. The breast cancer prognostic test helps in deciding for which patient a chemotherapy is indicated Further information is available at http://www.sividon.com or http://www.endopredict.com.

End of Media Release

More:
DJ Therapy decision in breast cancer: EndoPredict(R) predicts benefit from chemotherapy - Independent research group ...

Recommendation and review posted by Bethany Smith

ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of GeneAnalytics 1.0 at http://www.geneanalytics.com. GeneAnalytics is a powerful, yet easy to use, gene set analysis tool designed to help life scientists and biomedical researchers identify expression signatures and functionality of their experimental gene sets, and define their roles in various biological processes and in health and disease.

GeneAnalytics is powered by LifeMap Sciences popular integrated knowledgebase and discovery platform for biomedical research, which includes: GeneCards (http://www.genecards.org), the human gene database, LifeMap Discovery (http://discovery.lifemapsc.com), the embryonic development and stem cell database and MalaCards (http://www.malacards.org), the human disease database. LifeMap Sciences holds the exclusive worldwide license to market GeneCards and MalaCardsfrom Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.

LifeMap Sciences Biomedical Knowledgebase enables GeneAnalytics to analyze experimental gene sets of interest and match them toexpression patterns in various cell types, diseases and pathways and functional groups. It can aid in the discovery ofmarkers for tissues, cells and diseases, investigation ofdiseasemechanisms and in exploration of relationships between compounds and gene networks to enhance drug discovery. It is also a unique tool for characterization of tissue samples and cultured cells, assessment of their purity and analysis ofoutcomes of cell differentiation experiments.

GeneAnalytics is a key component of LifeMap Sciences recently launched premium platform, GeneCards Plus. The platform also includes GeneALaCart (http://genealacart.genecards.org), the GeneCards batch querying application and VarElect (http://varelect.genecards.org), the Next Generation Sequencing phenotyper.

Ronit Shtrichman, Ph.D., Vice President of Biology at LifeMap Sciences said, We believe that leveraging our extensive information and knowledgebase on biological entities, such as genes, cells, pathways, compounds and diseases, and the connections between these various entities to power gene set analysis by GeneAnalytics will enable it to significantly enhance basic biomedical research, stem cell research and therapeutic discovery.

In the few months since weve launched the beta version of GeneAnalytics, weve had over 1,000 scientists from academia and industry use it in their research, said Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. This is evidence that GeneAnalytics is a powerful research aid and we look forward to continuously improve its capabilities and features in upcoming releases, together with GeneALaCart and VarElect, our premium GeneCards Plus research tools.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its Integrated Biomedical Knowledgebase and discovery platform for biomedical research, which currently includesGeneCards: the leading human gene database;LifeMap Discovery, the database of embryonic development, stem cell research and regenerative medicine;MalaCards, the human disease database; and GeneAnalytics, a novel gene set analysis tool which leverages our Integrated Biomedical Knowledgebase. LifeMaps products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biotechnology and pharmaceutical companies.

LifeMap Sciences intends to continually improve the quality of its products, and is pursuing several new Internet and informatics products with substantial, rapid-revenue growth potential, leveraging its existing products and their large user base of life scientists. LifeMap also intends to extend its offerings to the field of mobile health via its subsidiaryLifeMap Solutions, Inc.

About BioTime

Read more:
LifeMap Sciences Announces Release and Commercial Availability of GeneAnalytics 1.0, a Powerful Gene Set Analysis ...

Recommendation and review posted by Bethany Smith

In a letter seen by the Sunday Times to the Commons science and technology committee, which is holding a one-day inquiry into three parent embryos on October 22, a group of scientists said: "The safety of mitochondrial replacement therapy is not yet established sufficiently well to proceed to clinical trials."

However, an editorial in New Scientist said mitochondria "play a key role in some of the most important features of human life. This raises the ethically troubling prospect ... that children conceived in this way will inherit vital traits from three parents."

Stuart Newman, a cell biologist and professor at New York Medical College, will submit his objections this week and said the importance of the outer part of the egg, donated by the second woman, was being played down.

"The mitochondria are ... participants in the development of the organism. This clearly makes any person [brought into being from the procedure] a product of wholesale genetic engineering," he said.

The Human Fertilisation and Embryology Authority, which backs mitochondrial replacement, said it could "see no reason for changing its in-depth and considered views on this matter".

Visit link:
Three-parent babies are 'genetic engineering' and be banned

Recommendation and review posted by Bethany Smith

Dr. Dimmock describes Genetics Genomics Program at Children #39;s Hospital of Wisconsin
Learn more about the Genetics and Genomics Program at Children #39;s Hospital of Wisconsin: http://bit.ly/1kERr5B Our Genetics and Genomics Program offers many s...

By: Children #39;s Hospital of Wisconsin

View post:
Dr. Dimmock describes Genetics & Genomics Program at Children's Hospital of Wisconsin - Video

Recommendation and review posted by Bethany Smith

New Genetics!- Buddha Kush OG and Euforia
Really happy about starting these two strains..I haven;t had a really great skunk strain in a coons age 🙂 Have a great day everyone and keep smiling p.s sorry for the shaking camera.

By: Major Burns

Original post:
New Genetics!- Buddha Kush OG and Euforia - Video

Recommendation and review posted by Bethany Smith

Speed Intro Genetics Artifacts

By: WooVan

Continued here:
Speed Intro Genetics Artifacts - Video

Recommendation and review posted by Bethany Smith

Invasive Species Genetics and Biogeography Research
University of Toledo website: http://www.utoledo.edu/index.html UT YouTube page: https://www.youtube.com/user/UToledo Department of Environmental Sciences website: http://www.utoledo.edu/nsm/envs...

By: DES Toledo

Visit link:
Invasive Species Genetics and Biogeography Research - Video

Recommendation and review posted by Bethany Smith

Gene therapy (1 of 4)
Created using PowToon -- Free sign up at http://www.powtoon.com/ . Make your own animated videos and animated presentations for free. PowToon is a free tool that allows you to develop...

By: Beau Johanan dela Cruz

Read the original here:
Gene therapy (1 of 4) - Video

Recommendation and review posted by Bethany Smith

Cookie - 9 Year Old Lab - Before Stem Cell Therapy
Watch the amazing after video here: https://www.youtube.com/watch?v=SRPO4OHKKlA.

By: Newman Veterinary Centers

Here is the original post:
Cookie - 9 Year Old Lab - Before Stem Cell Therapy - Video

Recommendation and review posted by simmons

Hari Sharma 4th Talk on Ubiquitin in Spinal cord Injury 12th ICNA Charlottesville, VA Sep 29, 2014

By: Hari Sharma

Read more here:
Hari Sharma 4th Talk on Ubiquitin in Spinal cord Injury 12th ICNA Charlottesville, VA Sep 29, 2014 - Video

Recommendation and review posted by sam

Stem cell therapy of a dog in the Netherlands.
One a half years later he is juming and playing after first almost not being able not walk anymore. info@fat-stem.com.

By: Fat Stem NV

Here is the original post:
Stem cell therapy of a dog in the Netherlands. - Video

Recommendation and review posted by Bethany Smith

Dr. Raj Live - Stem Cell Therapy
Dr. Raj discusses benefits of stem cell therapy.

By: SPORTSDOC RAJ

See the rest here:
Dr. Raj Live - Stem Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.

The results reported in the journal of Clinical Cancer Research, a publication of the American Association of Cancer Research, indicate the KLK3 gene -- a gene on chromosome 19 responsible for encoding the prostate-specific antigen (PSA) -- is not only associated with prostate cancer aggression, but a single nucleotide polymorphism (SNP) on it is more apparent in cancer patients with GS7.

Researchers have linked Gleason score, an important predictor of prostate cancer outcomes, to several clinical end points, including clinical stage, cancer aggression and survival. There has been much research associated with prostate cancer outcomes as well as GS7 prostate cancers, which is an intermediate grade of cancer accounting for 30 to 40 percent of all prostate cancers.

"This is the first report that I am aware of that indicates a genetic variant can stratify GS7 prostate cancer patients," said Jian Gu, Ph.D., associate professor at MD Anderson, and a key investigator on the study. "This is important because this group with heterogeneous prognosis is difficult to predict and there are no reliable biomarkers to stratify this group."

In this study, researchers investigated inherited genetic variants to see if there would be any promising biomarkers for prostate cancer patients. The investigators studied the genetic makeup of 72 SNPs identified from the genome-wide association studies (GWAS) in 1,827 prostate cancer patients. They analyzed associations of these SNPs with disease aggression, comparing them in clinically defined high and low aggressive cases. They found a SNP on the KLK3 gene that can predict an aggressive form of GS7 disease.

"Treatment options for the GS7 disease are controversial because the burden of combined treatment modalities may outweigh the potential benefit in some patients," said Xifeng Wu, M.D., Ph.D., professor and chair of Epidemiology, and lead investigator on the study. "It is critical that we develop personalized treatments based on additional biomarkers to stratify GS7 prostate cancers. Additional biomarkers may help us achieve personalized clinical management of low and intermediate risk prostate cancer patients."

Wu also said her team are expanding the study and taking a pathway-based approach to systemically investigate genetic variants in microRNA regulatory pathways as biomarkers for the prognosis of prostate cancer patients. "We are also working on circulating biomarkers. Eventually, we will incorporate all biomarkers, epidemiological and clinical variants into nomograms to best predict the prognosis of prostate cancer patients at diagnosis."

Story Source:

The above story is based on materials provided by University of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.

See original here:
Gene can predict aggressive prostate cancer at diagnosis

Recommendation and review posted by Bethany Smith

Breast Cancer Awareness: Stanford Doctor Explains Breast Cancer Genetics
Stanford Breast Cancer Expert, Alison Kurian, MD, explains the role that genetics play in the development of breast cancer. Kurian talks about how common breast cancer is, how genes are tested...

By: Stanford Health Care

Read more here:
Breast Cancer Awareness: Stanford Doctor Explains Breast Cancer Genetics - Video

Recommendation and review posted by Bethany Smith

Know What Your Smoking: Medical Cannabis Genetics, Strains Breeders
Always know what your smoking. Don #39;t get all razzle-dazzle over a Name. Its not about the Fancy Name, it all about the Genetics, the Medical Value and Effects~! Do your Homework on what you...

By: Godbody

Read the original:
Know What Your Smoking: Medical Cannabis Genetics, Strains & Breeders - Video

Recommendation and review posted by Bethany Smith

Mark Cuban on personalized medicine 1 2

By: Mike Chawaga

Continue reading here:
Mark Cuban on personalized medicine 1 2 - Video

Recommendation and review posted by sam

Aspen Regen Age Management Program

By: The Aspen Institute for Anti-Aging Regenerative Medicine

Continued here:
Aspen Regen Age Management Program - Video

Recommendation and review posted by sam

Stem Cell Therapy Walkthrough - Watch This Before Calling Or Scheduling
http://www.innovationsstemcellcenter.com Call: 214.420.7970 Facebook: https://www.facebook.com/innovationsmedical Twitter: https://twitter.com/dallasdrj Instagram: http://instagram.com/drbilljo...

By: dallasdrj

View post:
Stem Cell Therapy Walkthrough - Watch This Before Calling Or Scheduling - Video

Recommendation and review posted by simmons

New hope for multiple sclerosis sufferers By Cesar D. Mangawang |Philippine Daily Inquirer

FROM LEFT, Doctors Ana Martinez and Carmen Gil, Jose Mari Olbes and Jose Leviste, representing Jose Leviste III

The 2.4 million people suffering from multiple sclerosis worldwide have something to hope for with the discovery of a molecule which can be a key to creating a drug for the treatment of their ailment.

Dr. Ana Martinez, PhD, a research professor at the Spanish National Council for Research, revealed her patented molecular discovery during the launch of Ankar Pharma, the first Spanish-Filipino biotech company specializing in neurodegenerative diseases.

The revelation was made during a press conference held on Wednesday at the Zuellig Building in Makati where the management team showed up. The team is composed of Martinez, chief scientific officer; Dr. Carmen Gil, PhD, chief research officer; Jose Maria Olbes, vice president for business development; and Jose D. Leviste III, general counselor.

The company name was derived from the first names of the two female members of the management teamAna and Carmen, who was represented by Jose Leviste during the event.

Neurodegenerative diseases occur when the nervous system cells (neurons) in the brain and spinal cord begin to deteriorate. It is painful and heart-rending to see the health of a loved one who was once active deteriorate. Thats why the neurogenerative disease is a slow burn.

Multiple sclerosis is one of the worlds most common neurological disorders in many countries. It is the leading cause of nontraumatic disability in young adults.

Alzheimers and Parkinsons are the other neurodegenerative diseases. The number of people suffering from Alzheimers and Parkinsons diseases all over the world are 24 million and 7 million people, respectively.

With the help of investors from Spain and the Philippines, the biopharma company was created to develop a patented drug that promises to be a real game-changer.

Go here to see the original:
First Spanish-Filipino biotech firm introduced

Recommendation and review posted by simmons

Stem Cell Therapy: Helping the Body Heal Itself

Stem cells are natures own transformers. When the body is injured, stem cells travel the scene of the accident. Some come from the bone marrow, a modest number of others, from the heart itself. Additionally, theyre not all the same. There, they may help heal damaged tissue. They do this by secreting local hormones to rescue damaged heart cells and occasionally turning into heart muscle cells themselves. Stem cells do a fairly good job. But they could do better for some reason, the heart stops signaling for heart cells after only a week or so after the damage has occurred, leaving the repair job mostly undone. The partially repaired tissue becomes a burden to the heart, forcing it to work harder and less efficiently, leading to heart failure.

Initial research used a patients own stem cells, derived from the bone marrow, mainly because they were readily available and had worked in animal studies. Careful study revealed only a very modest benefit, so researchers have moved on to evaluate more promising approaches, including:

No matter what you may read, stem cell therapy for damaged hearts has yet to be proven fully safe and beneficial. It is important to know that many patients are not receiving the most current and optimal therapies available for their heart failure. If you have heart failure, and wondering about treatment options, an evaluation or a second opinion at a Center of Excellence can be worthwhile.

Randomized clinical trials evaluating these different approaches typically allow enrollment of only a few patients from each hospital, and hence what may be available at the Cleveland Clinic varies from time to time. To inquire about current trials, please call 866-289-6911 and speak to our Resource Nurses.

Cleveland Clinic is a large referral center for advanced heart disease and heart failure we offer a wide range of therapies including medications, devices and surgery. Patients will be evaluated for the treatments that best address their condition. Whether patients meet the criteria for stem cell therapy or not, they will be offered the most advanced array of treatment options.

Allogenic: from one person to another (for example: organ transplant)

Autogenic: use of one's own tissue

Myoblasts: immature muscle cells, may be able to change into functioning heart muscle cells

Stem Cells: cells that have the ability to reproduce, generate new cells, and send signals to promote healing

Excerpt from:
Stem-Cell Therapy and Repair after Heart Attack and Heart ...

Recommendation and review posted by Bethany Smith

Category: Science & Technology Posted: October 3, 2014 01:55PM Author: Guest_Jim_*

Heart attacks are pretty serious and something very hard to recover from, in part because heart cells do not multiply and there are few cardiac muscle stem cells to repair the damage. Cardiac patches have been created to replace damaged cells, but because of how they are made, these patches can cause their own health problems. Researchers at Tel Aviv University have recently developed a new hybrid patch that could address those problems.

Traditionally the patches are made by growing cardiac tissue on a collagen scaffold from pig hearts. One of the problems with this approach is the potential for antigens that will trigger an immune response, causing the patient's body to attack the patch. To get around this the researchers instead harvest fatty tissue from the patient's stomach, as the body will not attack its own cells. This left an issue with connectivity, as the cells in the patch must respond to the electrical signals of the heart, and engineered patches do not immediately form the necessary connections. The solution the researchers tried was to deposit gold nanoparticles onto the cardiac tissue, providing the needed conductivity.

So far the nonimmunogenic hybrid patch has shown itself to transfer electrical signals faster and more efficiently than scaffolds without the gold nanoparticles, when tested in animals. The next step for the technology is to test it in larger animals, and eventually perform clinical trials.

Source: American Friends of Tel Aviv University

Continue reading here:
Gold Nanoparticles Used to Improve Cardiac Patches

Recommendation and review posted by Bethany Smith

Garry Anderson was swept up in the tremendous community response in 1987 when Bruce Denniston was diagnosed with leukemia and needed a bone marrow transplant. Everyone got involved.

I went to school with Bruce Dennistons daughters, and lived in the same neighbourhood, Garry says. I remember the fundraisers.

Today, Garry is president of the Bruce Denniston Bone Marrow Society. Now the memory is getting scattered, and I worry that the name will be lost or wont mean as much. Many of the people who influenced and created the Society are retired or moving away.

Twenty-five years ago Bruce Denniston was described as the type of personality that everyone wishes he could have a share in. He was a loyal friend to many, a sportsman, and had more hobbies than most. He and his wife Joanne had three children and were active and popular in the community.

Bruce was diagnosed with myelocytic leukemia, a cancer of the blood-forming organs which seriously reduces the bodys ability to fight infection. He was 36 and had only missed one day of work in his 14-year career with the Royal Canadian Mounted Police (RCMP). He was told his best chance for recovery was a bone marrow transplant, but his siblings did not have the correct type of bone marrow.

Bruce needed help and Powell River people wanted to help him. They soon recognized a need for more unrelated bone marrow donors, and set about to improve the system for everyone.

Powell Rivers enthusiasm boosted the Canadian registry of unrelated bone marrow donors to a level where it could combine with the lists of other countries and thereby an international match was found for Bruce. The complete story, from hockey games to haircuts is available on the societys website.

When Bruce received the transplant the town rejoiced, but the roller-coaster of emotions continued with news that the chemotherapy that Bruce had undergone to prepare for the transplant had seriously weakened him. And, on February 12, 1989, Bruce died of liver and kidney failure.

RCMP Staff Sergeant Ron Mangan said at the time that the shock and sorrow were tempered with a degree of hope and pridehope that others being diagnosed with leukemia will now have access to an enlarged bone marrow bank. I think Powell River is a proud town, proud of Bruce and proud of their participation in the endeavour.

The work of the Bruce Denniston society continues in that legacy. Its mission is to improve the quality of life for those affected by blood-related illnesses and ensure a legacy so those who have gone before are not forgotten. In the past decades the society has led numerous fundraising events, donated to hospital upgrades, and supported Powell River residents when they received bone marrow transplants.

View original post here:
Remembering Denniston

Recommendation and review posted by Bethany Smith

T-cell Tuesday
T-cell Therapy infusion day.

By: Amanda Jensen

Read more:
T-cell Tuesday - Video

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer.

The results reported in the journal of Clinical Cancer Research, a publication of the American Association of Cancer Research, indicate the KLK3 gene a gene on chromosome 19 responsible for encoding the prostate-specific antigen (PSA) is not only associated with prostate cancer aggression, but a single nucleotide polymorphism (SNP) on it is more apparent in cancer patients with GS7.

Researchers have linked Gleason score, an important predictor of prostate cancer outcomes, to several clinical end points, including clinical stage, cancer aggression and survival. There has been much research associated with prostate cancer outcomes as well as GS7 prostate cancers, which is an intermediate grade of cancer accounting for 30 to 40 percent of all prostate cancers.

This is the first report that I am aware of that indicates a genetic variant can stratify GS7 prostate cancer patients, said Jian Gu, Ph.D., associate professor at MD Anderson, and a key investigator on the study. This is important because this group with heterogeneous prognosis is difficult to predict and there are no reliable biomarkers to stratify this group.

In this study, researchers investigated inherited genetic variants to see if there would be any promising biomarkers for prostate cancer patients. The investigators studied the genetic makeup of 72 SNPs identified from the genome-wide association studies (GWAS) in 1,827 prostate cancer patients. They analyzed associations of these SNPs with disease aggression, comparing them in clinically defined high and low aggressive cases. They found a SNP on the KLK3 gene that can predict an aggressive form of GS7 disease.

Treatment options for the GS7 disease are controversial because the burden of combined treatment modalities may outweigh the potential benefit in some patients, said Xifeng Wu, M.D., Ph.D., professor and chair of Epidemiology, and lead investigator on the study. It is critical that we develop personalized treatments based on additional biomarkers to stratify GS7 prostate cancers. Additional biomarkers may help us achieve personalized clinical management of low and intermediate risk prostate cancer patients.

Wu also said her team are expanding the study and taking a pathway-based approach to systemically investigate genetic variants in microRNA regulatory pathways as biomarkers for the prognosis of prostate cancer patients. We are also working on circulating biomarkers. Eventually, we will incorporate all biomarkers, epidemiological and clinical variants into nomograms to best predict the prognosis of prostate cancer patients at diagnosis.

Other MD Anderson co-authors include Yonggang He, M.D., Ph.D. and Sara Strom, Ph.D., of Epidemiology; Christopher Logothetis, M.D. and Jeri Kim, M.D., of Genitourinary Medical Oncology

Read more:
Researchers Discover Gene That Can Predict Aggressive Prostate Cancer at Diagnosis

Recommendation and review posted by Bethany Smith